clofazimine has been researched along with Acute Lung Injury in 1 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Acute Lung Injury: A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofazimine (CFZ) has attracted attention due to its anti-inflammatory property in immune diseases as well as infectious diseases." | 5.72 | Proteomic analysis and identification reveal the anti-inflammatory mechanism of clofazimine on lipopolysaccharide-induced acute lung injury in mice. ( Feng, FK; Gao, Z; Ji, LL; Li, QS; Li, W; Li, XP; Song, L; Wang, GS; Wang, R; Wang, XY; Wang, YN; Xie, H; Xu, HL; Yang, B; Zhang, XY, 2022) |
| "Clofazimine (CFZ) has attracted attention due to its anti-inflammatory property in immune diseases as well as infectious diseases." | 1.72 | Proteomic analysis and identification reveal the anti-inflammatory mechanism of clofazimine on lipopolysaccharide-induced acute lung injury in mice. ( Feng, FK; Gao, Z; Ji, LL; Li, QS; Li, W; Li, XP; Song, L; Wang, GS; Wang, R; Wang, XY; Wang, YN; Xie, H; Xu, HL; Yang, B; Zhang, XY, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, B | 1 |
| Gao, Z | 1 |
| Li, QS | 1 |
| Zhang, XY | 1 |
| Song, L | 1 |
| Wang, YN | 1 |
| Wang, XY | 1 |
| Ji, LL | 1 |
| Xu, HL | 1 |
| Xie, H | 1 |
| Feng, FK | 1 |
| Li, XP | 1 |
| Li, W | 1 |
| Wang, R | 1 |
| Wang, GS | 1 |
1 other study available for clofazimine and Acute Lung Injury
| Article | Year |
|---|---|
Proteomic analysis and identification reveal the anti-inflammatory mechanism of clofazimine on lipopolysaccharide-induced acute lung injury in mice.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Chromatography, Liquid; Clofazimine; COVID-19 | 2022 |